MannKind Corporation

MNKD Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$2.50

-1.57% today

52W: $2.23 – $6.51

52W Low: $2.23 Position: 6.3% 52W High: $6.51

🔗 Compare Brokers

Key Metrics

P/E Ratio

125x

Price-to-Earnings

Forward P/E

10.99x

Forward Price/Earnings

P/S Ratio

2.21x

Price-to-Sales

EV/EBITDA

18.18x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$770.3M

Market Capitalization

Revenue Growth

45.8%

YoY Revenue Growth

Profit Margin

1.68%

Net profit margin

ROE

—

Return on Equity

Beta

1.04

Market sensitivity

Short Interest

7.48%

% of float sold short

Avg. Volume

5,936,180

Average daily volume

Valuation Analysis

Signal

Overvalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

9 analysts

Avg. Price Target

$7.50

+200% upside

Target Range

$3.50 – $10.00

About the Company

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 591 Exchange: NGM